Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

Mayo Clinic

Summary

This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.

Eligibility

Age range: Up to 21 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team * Receiving calaspargase as part of treatment for malignancy Exclusion Criteria: * Age \> 21 years * Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm * Pregnancy

Interventions

Other
Non-Interventional Study
Non-interventional study

Location

Mayo Clinic in Rochester
Rochester, Minnesota
mayocliniccancerstudies@mayo.edu 855-776-0015